Clinical Trial

Phase II Study of Reuse of Oxaliplatin Hypersensitivity in Gastrointestinal Tumors

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated June 28, 2023 (before its estimated September 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
The incidence of oxaliplatin allergy reactions is between 12-15%, while the incidence of severe (grade 3-4) allergic reactions is between 0.5-2%. The purpose of this study is to prospectively investigate the incidence of oxaliplatin allergy and neurotoxicity, and to evaluate the use of effective anti-allergic and desensitization therapies to enable patients who are already allergic to oxaliplatin to complete their prescribed doses smoothly.
Trial Details
NCT Number NCT05922358
Lead Sponsor Fujian Cancer Hospital
Conditions Gastrointestinal Tumors
Enrollment 500 participants
Start Date 2023-09-01
Primary Completion 2025-09-01 (estimated)
Study Completion 2026-09-01 (estimated)
Updated on ClinicalTrials.gov 2023-06-28